Jason Zemansky

“I may this may seem like a random question now but as we think about the evolving treatment paradigm it looks like Biogen is now positioning Lequembe as a follow-on after denanumab clears plaque and you know the argument is that soluble species sort of keep driving disease after the plaque is gone so it seems like a…”

“Maybe to start, it's probably fair to say a key determinant of success and altitude will be the placebo arm. So given the use of the P-tau screening, the relatively high proportion of MCI patients and some of the similarities you've highlighted with Clarity, how should investors think about placebo decline?”

“Maybe to start, it's probably fair to say a key determinant of success and altitude will be the placebo arm. So given the use of the P-tau screening, the relatively high proportion of MCI patients and some of the similarities you've highlighted with Clarity, how should investors think about placebo decline?”

“You described altitude, I guess, is designed to detect a STAT-SIG difference in IDRIS. But with two active doses, can you clarify the framework and whether each dose is independently powered against placebo?”